Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Don Haut

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Jan 08, 2021 9:36am

161 Views

Post# 32252762

RE:RE:Don Haut

Youre right. Even the economic studies commisioned by ATE had similiar (and very conservative) first year estimates.

Normally, its the analysts working for instos that do this. But ATE did the work for them, through a third party, to speed up their investing process.

Dan and JLW are looking for an exit strategy, so JLW can get his emeritus on, and Dan can retire on his farm haha.

TriumphSpitSix wrote: Dr. Haut commented, “Antibe’s platform promises a major advance in the treatment of pain and inflammation-based disease. This area is overdue for disruption and represents a massive commercial opportunity. I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.”

Seems the proverbial writing is on the wall... Full drug pipeline acquisition: OTEN, 352, 340, the whole schmiel. What the hell, since I'm playing with my crystal balls, I'll call it too: $12 Billion.

That's just 1/2 the projected one-year market for NSAIDs in 2027 according to this article:

https://www.globenewswire.com/news-release/2020/05/28/2040374/0/en/NSAIDs-Market-to-Reach-USD-24-35-Billion-by-2027-Surging-Research-on-Selective-Cyclooxygenase-2-Inhibitors-to-Boost-Growth-Fortune-Business-Insights.html